FDA clears Abbott's dual-energy ablation catheter for complex AFib
New CapabilitiesTactiFlex Duo combines pulsed field and radiofrequency energy in a single device.
Yesterday: FDA approves TactiFlex Duo dual-energy catheterNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated YesterdayThe Food and Drug Administration cleared Abbott's TactiFlex Duo, the first U.S. ablation catheter to combine pulsed field and radiofrequency energy. The device is designed for complex atrial fibrillation, a condition affecting about 10.5 million Americans.
The approval rests on 12-month data from the FlexPulse study. 74.6% of patients stayed free of arrhythmias, and 92.6% had no recurrence under standard monitoring. Abbott says U.S. commercial cases will begin within weeks.
Why it matters
It gives doctors a single tool to switch energy types mid-procedure, which could reduce repeat ablations for millions of AFib patients.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
Organizations Involved
Global healthcare leader with a growing electrophysiology division.
Federal agency responsible for protecting public health by regulating medical devices.
Timeline
May 2023 September 2026
-
FDA approves TactiFlex Duo dual-energy catheter
Latest Regulatory ApprovalFirst U.S. approval for a catheter combining pulsed field and radiofrequency energy.
-
TactiFlex Duo receives European CE mark
Regulatory ApprovalDual-energy catheter gains European approval in January.
-
FDA approves Volt PFA system in the U.S.
Regulatory ApprovalVolt becomes Abbott's first U.S.-approved pulsed field ablation system.
-
Volt PFA receives European CE mark
Regulatory ApprovalAbbott's pulsed field ablation system gains approval in Europe.
-
FDA clears original TactiFlex catheter
Regulatory ApprovalCleared the RF-only version of TactiFlex for cardiac ablation.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Arctic Front Cryoballoon FDA approval (2010)
Medtronic's Arctic Front cryoballoon was the first major ablation technology shift in a decade. It used frozen balloons to isolate pulmonary veins, offering an alternative to point-by-point radiofrequency ablation.
Cryoballoon became a workhorse for treating paroxysmal AFib across Europe and the U.S.
It established catheter ablation as a mainstream therapy, leading to the current PFA and dual-energy era.
Shows how new ablation technologies move from first approval to standard of care, a pattern the TactiFlex Duo aims to follow.
Edwards Sapien TAVR approval (2011)
The FDA approved the first transcatheter aortic valve replacement, allowing severely ill patients to avoid open-heart surgery. Edwards Lifesciences' Sapien valve was initially limited to high-risk patients.
TAVR was quickly adopted, expanding to intermediate and low-risk patients within a few years.
TAVR became the standard of care, transforming how heart valve disease is treated worldwide.
Demonstrates how a novel technical capability in a single device can rapidly expand its approved patient population and displace older surgical approaches.
Medtronic PulseSelect PFA approval (2023)
The FDA cleared the first pulsed field ablation catheter for atrial fibrillation, reshaping the cardiac ablation market. Medtronic's PulseSelect system delivered targeted electric fields to heart tissue without the heat or cold effects of older methods.
PFA quickly became a preferred option for paroxysmal AFib due to lower complication rates.
PFA adoption surged, prompting competitors like Abbott, Boston Scientific, and J&J to accelerate their own programs.
Set the stage for the current competitive battlefield. Abbott's dual-energy device is the next step beyond this single-energy breakthrough.
